Next-generation proteasome inhibitors for cancer therapy
Article
Park, JE, Miller, Z, Jun, Y et al. (2018). Next-generation proteasome inhibitors for cancer therapy
. TRANSLATIONAL RESEARCH, 198 1-16. 10.1016/j.trsl.2018.03.002
Park, JE, Miller, Z, Jun, Y et al. (2018). Next-generation proteasome inhibitors for cancer therapy
. TRANSLATIONAL RESEARCH, 198 1-16. 10.1016/j.trsl.2018.03.002
Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic target. Today, proteasome inhibitors are a mainstay in the treatment of multiple myeloma (MM) and have sales in excess of 3 billion US dollars annually. More importantly, the availability of proteasome inhibitors has greatly improved the survival and quality of life for patients with MM. Despite the remarkable success of proteasome inhibitor therapies to date, the potential for improvement remains, and the development and optimal use of proteasome inhibitors as anticancer agents continues to be an active area of research. In this review, we briefly discuss the features and limitations of the 3 proteasome inhibitor drugs currently used in the clinic and provide an update on current efforts to develop next-generation proteasome inhibitors with the potential to overcome the limitations of existing proteasome inhibitor drugs.
